Drug intelligence / Profile preview

MTBVAC PRIME

Development stage: Unknown
Lead developer: Biofabri
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

MTBVAC PRIME is a live-attenuated vaccine candidate for tuberculosis (TB) designed specifically for use in newborns. It is based on a genetically modified clinical isolate of Mycobacterium tuberculosis (Euro-American lineage), with two independent nonreverting deletion mutations in the virulence genes phoP and fadD26. This vaccine aims to stimulate immune responses that mimic natural TB infection without causing disease, and it contains the full set of antigenic targets present in virulent M. tuberculosis, including T cell epitopes absent in BCG (the current standard TB vaccine). The development was led by Dr. Carlos Martín Montañés at the University of Zaragoza and Brigitte Gicquel at Institut Pasteur[2][4][5].

Brand names: MTBVAC PRIME
Other names: MTBVAC PRIMEMTBVAC for newborns

Beyond the preview

Go deeper on MTBVAC PRIME.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTBVAC PRIME.

Explore the full profile